Dogecoin Cash, Inc. (OTC: DOGP)

Dogecoin Cash, Inc. is a Nevada incorporated company that was originally formed in November 2004 under the name Ultra Sun Corporation and later changed to Cannabis Sativa, Inc. before adopting its current name. The Company presently conducts its principal operations through its majority owned subsidiary PrestoCorp, Inc. which does business as PrestoDoctor. The core activity of the Company is to provide a technology platform that enables telemedicine consultations between patients and licensed physicians for medical cannabis evaluations. The service is delivered via secure video connections in jurisdictions where such evaluations are permitted under state law. The Company supplies the administrative support and technical infrastructure while the physicians remain independent medical professionals responsible for the care they provide. Although the Firm holds certain cannabis related intellectual property and explores digital asset initiatives through subsidiaries those activities remain ancillary to its main telemedicine business.

The Company generates essentially all of its revenue from fees charged for telemedicine consultations conducted through the PrestoDoctor platform. Patients access the service by scheduling appointments online and are connected with licensed physicians who perform medical cannabis evaluations via secure video. The Company retains a portion of the consultation fee as compensation for providing the technology platform administrative support and patient acquisition. Its asset light model avoids the costs of owning physical clinics or employing physicians directly which allows it to scale quickly as demand changes. In addition to per visit charges the platform may offer bundled packages or promotional credits that also contribute to overall revenue. Consequently the revenue stream is closely tied to the volume of completed consultations and the pricing structure set by the platform.

The company operates through a single reportable operating segment that encompasses its telemedicine services. This segment is represented by the operations of PrestoCorp, Inc. doing business as PrestoDoctor. No separate geographical or product based segments are reported in the filings.

• The Telemedicine services segment consists of the PrestoDoctor platform that schedules and conducts remote medical cannabis evaluations between patients and licensed physicians. The Company supplies the secure video technology administrative support and patient acquisition while the physicians remain independent practitioners responsible for the clinical service. Operations are limited to states where medical cannabis evaluations are allowed under local law and the platform follows an asset light approach without owning clinics or employing physicians directly. The technology includes encrypted video links electronic health record integration and identity verification tools to meet privacy requirements. This focus enables the Company to serve a specific niche within the broader telehealth industry and provides a foundation for potential expansion into related telehealth services.

The Company operates in a competitive telehealth market where many rivals possess greater financial backing larger physician networks and more advanced technology platforms. Its competitive advantage lies in the specialized focus on medical cannabis evaluations and the asset light model that reduces fixed costs. The proprietary scheduling and video technology developed for PrestoDoctor provides a reliable and secure user experience for both patients and physicians. While larger competitors may offer broader telehealth services the Company’s niche orientation allows it to capture demand in states where medical cannabis evaluations are permitted. The Firm also emphasizes compliance with health privacy laws such as HIPAA which is important for patients and physicians alike. Despite the scale advantages of larger operators the Company’s lean structure enables it to adapt quickly to regulatory changes and market opportunities.

The Company’s customers consist of patients who seek medical cannabis evaluations for treatment purposes and licensed physicians who conduct those evaluations through the PrestoDoctor platform. Patients typically reside in states that have authorized medical cannabis programs and require a physician recommendation to access the treatment. Physicians using the service are independent practitioners who value the platform’s ability to connect them with eligible patients without the overhead of a physical clinic. The patient base includes individuals managing chronic pain anxiety and other qualifying conditions as defined by state law. Physicians often join the network to supplement their income and to provide a telehealth option that fits their practice style. The Company does not disclose individual patient or physician names in its public filings.